Aurinia Pharmaceuticals Inc $AUPH Stock Position Decreased by Fox Run Management L.L.C.

Fox Run Management L.L.C. decreased its holdings in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 20.2% during the 2nd quarter, Holdings Channel.com reports. The fund owned 35,861 shares of the biotechnology company’s stock after selling 9,101 shares during the period. Fox Run Management L.L.C.’s holdings in Aurinia Pharmaceuticals were worth $304,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of AUPH. Cerity Partners LLC bought a new position in shares of Aurinia Pharmaceuticals during the first quarter valued at approximately $96,000. Xponance Inc. acquired a new position in Aurinia Pharmaceuticals during the 1st quarter valued at approximately $82,000. CWM LLC grew its stake in Aurinia Pharmaceuticals by 66.1% during the 1st quarter. CWM LLC now owns 21,944 shares of the biotechnology company’s stock worth $176,000 after buying an additional 8,733 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new stake in Aurinia Pharmaceuticals in the first quarter worth $1,688,000. Finally, IFP Advisors Inc increased its position in Aurinia Pharmaceuticals by 2.4% in the first quarter. IFP Advisors Inc now owns 277,580 shares of the biotechnology company’s stock worth $2,232,000 after buying an additional 6,448 shares during the period. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on AUPH shares. HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Bloom Burton cut shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Jefferies Financial Group upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the company from $10.00 to $21.00 in a research note on Friday, November 7th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $15.00 price objective (up from $9.00) on shares of Aurinia Pharmaceuticals in a research report on Wednesday, November 5th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Aurinia Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $17.67.

Aurinia Pharmaceuticals Stock Down 2.1%

Aurinia Pharmaceuticals stock opened at $15.22 on Friday. Aurinia Pharmaceuticals Inc has a 52 week low of $6.55 and a 52 week high of $16.20. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of 35.40 and a beta of 1.30. The company’s 50-day moving average price is $12.54 and its two-hundred day moving average price is $10.37. The company has a current ratio of 5.23, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.07. Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The business had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $67.70 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.